The pharmacological activity of nicotine and nornicotine on nAChRs subtypes: Relevance to nicotine dependence and drug discovery

Journal of Neurochemistry

Volumn 101, Issue 1, 2007, Pages 160-167

  Papke, Roger L ^a   Dwoskin, Linda P ^b   Crooks, Peter A ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b University of Kentucky   (United States)

Author keywords

Dopamine release; Nicotine metabolism; Voltage clamp; Xenopus oocytes

Indexed keywords

BUNGAROTOXIN RECEPTOR; DOPAMINE; NICOTINE; NICOTINIC RECEPTOR; NORNICOTINE; RECEPTOR SUBTYPE;

ACETYLCHOLINE BRAIN LEVEL; ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG TARGETING; FEMALE; LIGAND BINDING; NONHUMAN; OOCYTE; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; SCHIZOPHRENIA; TOBACCO DEPENDENCE; XENOPUS;

ACETYLCHOLINE; ANIMALS; BRAIN; BRAIN CHEMISTRY; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; NICOTINE; NICOTINIC AGONISTS; OOCYTES; PROTEIN SUBUNITS; RATS; RECEPTORS, NICOTINIC; RECOMBINANT FUSION PROTEINS; TOBACCO USE DISORDER; XENOPUS;

NICOTIANA TABACUM;

EID: 33947275186     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04355.x     Document Type: Article

References (60)

1. Bardo M. T., Bevins R. A., Klebaur J. E., Crooks P. A. and Dwoskin L. P. (1997) (-)-Nornicotine partially substitutes for (+)-amphetamine in a drug discrimination paradigm in rats. Pharmacol. Biochem. Behav. 58, 1083-1087.
2. Benowitz N. L., Jacob P. III, Denaro C. and Jenkins R. (1991) Stable isotope studies of nicotine kinetics and bioavailability. Clin. Pharmacol. Ther. 49, 270-277.
3. Bowman E. R., Turnbull L. B. and Mc K. H. Jr (1959) Metabolism of nicotine in the human and excretion of pyridine compounds by smokers. J. Pharmacol. Exp. Ther. 127, 92-95.
4. Caskey N. H., Jarvik M. E. and Wirshing W. C. (1999) The effects of dopaminergic D2 stimulation and blockade on smoking behavior. Exp. Clin. Psychopharmacol. 7, 72-78.
5. Champtiaux N., Gotti C., Cordero-Erausquin M. et al. (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J. Neurosci. 23, 7820-7829.
6. Clarke P. B. (1990) Mesolimbic dopamine activation - the key to nicotine reinforcement? Ciba Found. Symp. 152, 153-168.
7. Copeland J. R., Adem A., Jacob P. III and Nordberg A. (1991) A comparison of the binding of nicotine and nornicotine stereoisomers to nicotinic binding sites in rat brain cortex. Naunyn Schmiedebergs Arch. Pharmacol. 343, 123-127.
8. Corrigall W. A. and Coen K. M. (1991) Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl.) 104, 171-176.
9. Corrigall W. A., Franklin K. B., Coen K. M. and Clarke P. B. (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl.) 107, 285-289.
10. Corrigall W. A., Coen K. M. and Adamson K. L. (1994) Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. 653, 278-284.
11. Crooks P. A. and Dwoskin L. P. (1997a) Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem. Pharmacol. 54, 743-753.
12. Crooks P. A. and Dwoskin L. P. (1997b) Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem. Pharmacol. 54, 743-753.
13. Crooks P. A., Li M. and Dwoskin L. P. (1995) Determination of nicotine metabolites in rat brain after peripheral radiolabeled nicotine administration: detection of nornicotine. Drug Metab. Dispos. 23, 1175-1177.
14. Cundy K. C. and Crooks P. A. (1984) High-performance liquid chromatographic method for the determination of N-methylated metabolites of nicotine. J. Chromatogr. 306, 291-301.
15. Curvall M. and Kazeni V. E. (1993) Nicotine and metabolites: analysis and levels in body fluids, in Nicotine and Related Alkaloids: Absorption, Distribution, Metabolism and Excretion (Gorrod J. W. and Wahren J., eds.), pp. 147-179. Chapman Hall, London.
16. Dani J. A. (2001) Overview of nicotinic receptors and their roles in the central nervous system. Biol. Psychiatry 49, 166-174.
17. Dawe S., Gerada C., Russell M. A. and Gray J. A. (1995) Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology (Berl.) 117, 110-115.
18. Desai R. I., Barber D. J. and Terry P. (1999) Asymmetric generalization between the discriminative stimulus effects of nicotine and cocaine. Behav. Pharmacol. 10, 647-656.
19. Desai R. I., Barber D. J. and Terry P. (2003) Dopaminergic and cholinergic involvement in the discriminative stimulus effects of nicotine and cocaine in rats. Psychopharmacology (Berl.) 167, 335-343.
20. Dowell C., Olivera B. M., Garrett J. E., Staheli S. T., Watkins M., Kuryatov A., Yoshikami D., Lindstrom J. M. and McIntosh J. M. (2003) Alpha-conotoxin PIA is selective for alpha6 subunit-containing nicotinic acetylcholine receptors. J. Neurosci. 23, 8445-8452.
21. Dwoskin L. P., Buxton S. T., Jewell A. L. and Crooks P. A. (1993) S(-)-nornicotine increases dopamine release in a calcium-dependent manner from superfused rat striatal slices. J. Neurochem. 60, 2167-2174.
22. Gerzanich V., Kuryatov A., Anand R. and Lindstrom J. (1996) "Orphan" α6 nicotinic AChR subunit can form a functional heteromeric acetylcholine receptor. Mol. Pharmacol. 51, 320-327.
23. Gerzanich V., Wang F., Kuryatov A. and Lindstrom J. (1998) alpha 5 Subunit alters desensitization, pharmacology, Ca++ permeability and Ca++ modulation of human neuronal alpha 3 nicotinic receptors. J. Pharmacol. Exp. Ther. 286, 311-320.
24. Ghosheh O., Dwoskin L. P., Li W. K. and Crooks P. A. (1999) Residence times and half-lives of nicotine metabolites in rat brain after acute peripheral administration of [2′-(14)C]nicotine. Drug Metab. Dispos. 27, 1448-1455.
25. Ghosheh O. A., Dwoskin L. P., Miller D. K. and Crooks P. A. (2001) Accumulation of nicotine and its metabolites in rat brain after intermittent or continuous peripheral administration of [2′- (14)C]nicotine. Drug Metab. Dispos. 29, 645-651.
26. Goldberg S. R., Risner M. E., Stolerman I. P., Reavill C. and Garcha H. S. (1989) Nicotine and some related compounds: effects on schedule-controlled behaviour and discriminative properties in rats. Psychopharmacology 97, 295-302.
27. Grady S., Marks M. J., Wonnacott S. and Collins A. C. (1992) Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem. 59, 848-856.
28. Grady S. R., Murphy K. L., Cao J., Marks M. J., McIntosh J. M. and Collins A. C. (2002) Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions. J. Pharmacol. Exp. Ther. 301, 651-660.
29. Green T. A., Crooks P. A., Bardo M. T. and Dwoskin L. P. (2001) Contributory role for nornicotine in nicotine neuropharmacology: nornicotine-evoked [3H]dopamine overflow from rat nucleus accumbens slices. Biochem. Pharmacol. 62, 1597-1603.
30. Green T. A., Brown R. W., Phillips S. B., Dwoskin L. P. and Bardo M. T. (2002) Locomotor stimulant effects of nornicotine: role of dopamine. Pharmacol. Biochem. Behav. 74, 87-94.
31. Howard L. A., Micu A. L., Sellers E. M. and Tyndale R. F. (2001) Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. J. Pharmacol. Exp. Ther. 299, 542-550.
32. Howard L. A., Miksys S., Hoffmann E., Mash D. and Tyndale R. F. (2003) Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br. J. Pharmacol. 138, 1376-1386.
33. Jacob P. and Benowitz N. L. (1993) Pharmacokinetics of S(-)-nicotine and metabolites in humans, in Nicotine and Related Alkaloids: Absorption, Distribution, Metabolism and Excretion (Gorrod J. W. and Wahren J., eds.), pp. 197-218. Chapman Hall, London.
34. Ji D., Lape R. and Dani J. A. (2001) Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron 31, 131-141.
35. Kisaki T. and Tamaki E. (1961) Phytochemical studies on the tobacco alkaloids. I. Optical rotatory power of nornicotine. Arch. Biochem. Biophys. 92, 351-355.
36. Kuryatov A., Olale F., Cooper J., Choi C. and Lindstrom J. (2000) Human alpha6 AChR subtypes: subunit composition, assembly, and pharmacological responses. Neuropharmacology 39, 2570-2590.
37. Louis M. and Clarke P. B. (1998) Effect of ventral tegmental 6-hydroxydopamine lesions on the locomotor stimulant action of nicotine in rats. Neuropharmacology 37, 1503-1513.
38. Mattila M. (1963) Pharmacological properties of some pyrrolidine N-substituted nornicotine derivatives. Ann. Med. Exp. Biol. 41, 1-92.
39. McKennis H., Turnbull L. B., Schwartz S. L., Tamaki E. and Bowman E. R. (1962) Demethylation in the metabolism of (-)-nicotine. J. Biol. Chem. 237, 541-546.
40. Moyer T. P., Charlson J. R., Enger R. J., Dale L. C., Ebbert J. O., Schroeder D. R. and Hurt R. D. (2002) Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. Clin. Chem. 48, 1460-1471.
41. Papke R. L. and Heinemann S. F. (1994) The partial agonist properties of cytisine on neuronal nicotinic receptors containing the β2 subunit. Mol. Pharm. 45, 142-149.
42. Papke R. L. and Papke J. K. P. (2002) Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis. Br. J. Pharmacol. 137, 49-61.
43. Papke R. L., Webster J. C., Lippiello P. M., Bencherif M. and Francis M. M. (2000) The activation and inhibition of human nAChR by RJR-2403 indicate a selectivity for the α4β2 receptor subtype. J. Neurochem. 75, 204-216.
44. Papke R. L., Buhr J. D., Francis M. M., Choi K. I., Thinschmidt J. S. and Horenstein N. A. (2005) The effects of subunit composition on the inhibition of nicotinic receptors by the amphipathic blocker 2,2,6,6-tetramethylpiperidin-4- yl heptanoate. Mol. Pharmacol. 67, 1977-1990.
45. Picciotto M., Zoli M., Rimondini R., Lena C., Marubio L., Pich E., Fuxe K. and Changeux J. (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391, 173-177.
46. Reavill C., Jenner P., Kumar R. and Stolerman I. P. (1988) High affinity binding of [3H] (-)-nicotine to rat brain membranes and its inhibition by analogues of nicotine. Neuropharmacology 27, 235-241.
47. Risner M. E., Goldberg S. R., Prada J. A. and Cone E. J. (1985) Effects of nicotine, cocaine and some of their metabolites on schedule-controlled responding by beagle dogs and squirrel monkeys. J. Pharmacol. Exp. Ther. 234, 113-119.
48. Risner M. E., Cone E. J., Benowitz N. L. and Jacob P. III (1988) Effects of the stereoisomers of nicotine and nornicotine on schedule-controlled responding and physiological parameters of dogs. J. Pharmacol. Exp. Ther. 244, 807-813.
49. Rosecrans J. A. and Meltzer L. T. (1981) Central sites and mechanisms of action of nicotine. Neurosci. Biobehav. Rev. 5, 497-501.
50. Salminen O., Murphy K. L., McIntosh J. M., Drago J., Marks M. J., Collins A. C. and Grady S. R. (2004) Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 65, 1526-1535.
51. Stokes C., Papke J. K. P., McCormack T., Kem W. R., Horenstein N. A. and Papke R. L. (2004) The structural basis for drug selectivity between human and rat nicotinic alpha7 receptors. Mol. Pharm. 66, 14-24.
52. Stolerman I. P. and Jarvis M. J. (1995) The scientific case that nicotine is addictive. Psychopharmacology (Berl.) 117, 2-10; discussion 14-20.
53. Swango J. H., Bhatti B. S., Qureshi M. M. and Crooks P. A. (1999) A novel enantioselective synthesis of (S)-(-)- and (R)-(+)-nornicotine via alkylation of a chiral 2-hydroxy-3-pinanone ketimine template. Chirality 11, 316-318.
54. Teng L., Crooks P. A., Buxton S. T. and Dwoskin L. P. (1997) Nicotinic-receptor mediation of S(-)nornicotine-evoked -3H-overflow from rat striatal slices preloaded with -3H-dopamine. J. Pharmacol. Exp. Ther. 283, 778-787.
55. Tsai M. C. and Gorrod J. W. (1999) In vitro metabolism of (S)-(-)-[2′-14C]nicotine, using various tissue preparations of marmoset. Drug Metabol. Drug Interact. 15, 97-105.
56. Valette H., Bottlaender M., Dolle F., Coulon C., Ottaviani M. and Syrota A. (2003) Long-lasting occupancy of central nicotinic acetylcholine receptors after smoking: a PET study in monkeys. J. Neurochem. 84, 105-111.
57. Wang F., Gerzanich V., Wells G. B., Anand R., Peng X., Keyser K. and Lindstrom J. (1996) Assembly of human neuronal nicotinic receptor α5 subunits with α3, β2 and β4 subunits. J. Biol. Chem. 271, 17 656-17 665.
58. Whiteaker P., Jimenez M., McIntosh J. M., Collins A. C. and Marks M. J. (2000) Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine. Br. J. Pharmacol. 131, 729-739.
59. Zhang X. and Nordberg A. (1993) The competition of (-)-[3H]nicotine binding by the enantiomers of nicotine, nornicotine and anatoxin-a in membranes and solubilized preparations of different brain regions of rat. Naunyn Schmiedebergs Arch. Pharmacol. 348, 28-34.
60. Zoli M., Moretti M., Zanardi A., McIntosh J. M., Clementi F. and Gotti C. (2002) Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci. 22, 8785-8789.